MedTrace Logo

Imagery as Biomarker of Gout

NCT05434858 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-09-10

No results posted yet for this study

Summary

The objective of this study is to determine whether MSU crystal deposits visualized on ultrasound and/or DECT are associated with the development of symptomatic gout (according to ACR 2015 / EULAR criteria) over 5 years in hyperuricemic individuals.

Conditions

  • Hyperuricemia

Interventions

OTHER

Dual-energy CT (DECT) and ultrasound

DECT and ultrasound will be performed to clarify the pathological mechanisms responsible for the transition from asymptomatic crystalline deposition to gout, and the mechanisms involved in the transition from hyperuricemia to de novo crystalline deposition.

Sponsors & Collaborators

  • Auckland University

    collaborator UNKNOWN

  • Lille Catholic University

    lead OTHER

Principal Investigators

  • Tristan Pascart, MD, PhD · Lille Catholic University

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-09
Primary Completion
2024-08-31
Completion
2029-09-09

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05434858 on ClinicalTrials.gov